| Therapeutic | Lanadelumab |
| Target | KLKB1 |
| Heavy Chain | EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYIMMWVRQAPGKGLEWVSGIYSSGGITVYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAYRRIGVPRRDEFDIWGQGTMVTVSS |
| Light Chain | DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASTLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNTYWTFGQGTKVEIK |
| 100% seqID Fv Structure | 4ogx [Fvs: HL], 4ogy [Fvs: HL, MN], 4pub [Fvs: HL] |
| 99% seqID Fv Structure | None |
| 95-98% seqID Fv Structure | None |
| 100% seqID Structure | 4pub [Fvs: HL] |
| 100% seqID Structure | 4ogy [Fvs: HL, MN] |
| 100% seqID Structure | 4ogx [Fvs: HL] |
Follow these links to our prediction tools:
| Format | Whole mAb |
| Isotype | G1 |
| Highest Clinical Trial (June '19) | Approved |
| Estimated Status (June '19) | NFD |
| Recorded Developmental Technology | na |
| INN Year Proposed | 2015 |
| INN Year Recommended | 2016 |
| Companies Involved | Dyax, Shire, Takeda |
| Conditions Approved | Hereditary angioedema |
| Conditions Active | na |
| Conditions Discontinued | Diabetic macular oedema |
| Notes |
